InsiderTrades

Form 4 for PFE Pfizer

Accepted 2025-02-25 00:00:00 ET · period of report 2025-02-22 · accession 0001225208-25-002402 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-02-25 2025-02-22 PFE BOURLA ALBERT COB, CEO, Dir M - OptEx $30.17 +238.4K 570.4K +72% +$7.19M
DM 2025-02-25 2025-02-22 PFE BOURLA ALBERT COB, CEO, Dir F - Tax $26.09 -221.5K 348.9K -39% -$5.78M
D 2025-02-25 2025-02-22 PFE BOURLA ALBERT COB, CEO, Dir M - OptEx $0.00 -238.4K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-22 M A 238,399 $30.17 570,436 D — — (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
2 Common Common Stock 2025-02-22 F D 8,835 $26.30 561,601 D — — (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. (F3) Price is the closing price of Pfizer common stock on February 21, 2025.
3 Common Common Stock 2025-02-22 F D 212,680 $26.08 348,921 D — — (F4) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F5) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
4 Derivative Stock Appreciation Rights 2025-02-22 M D 238,399 $0.00 0 D $30.17 · 2025-02-22 to 2025-02-22 238,399 Common Stock